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ABSTRACT
Background: Vascular endothelial growth factor (VEGF)
and its receptor may have an important role in the
pathogenesis of emphysema. The effect of another
angiogenic factor, placenta growth factor (PlGF), in
chronic obstructive pulmonary disease (COPD) is
unknown.
Methods: The serum levels of VEGF and PlGF in patients
with COPD (n=184), smokers (n=212) and non-
smokers (n=159) and the bronchoalveolar lavage (BAL)
fluid levels of VEGF and PlGF in another group (20 patients
with COPD, 18 controls) were measured. In vitro cell
culture experiments were performed to investigate the
effect of PlGF on VEGF.
Results: The mean (SE) serum levels of PlGF were
significantly higher in patients with COPD than in controls
(27.1 (7.4) pg/ml vs 12.3 (5.1) pg/ml in smokers and 10.8
(6.3) pg/ml in non-smokers, p=0.005). The levels of
PlGF in BAL fluid were also significantly higher in patients
with COPD than in controls (45.7 (12.3) pg/ml vs 23.9
(7.6) pg/ml, p=0.005), associated with an increase in
the cytokines tumour necrosis factor-a (TNF-a) and
interleukin-8 (IL-8). In patients with COPD the levels of
PlGF correlated inversely with forced expiratory volume in
1 s (FEV1) in serum (r=20.59, p=0.002) and in BAL
fluid (r=20.51, p=0.001). While the serum levels of
VEGF were the same in patients with COPD and controls,
the BAL fluid levels were significantly lower in patients
with COPD than in controls (127.5 (30.1) pg/ml vs 237.8
(36.1) pg/ml, p=0.002). In cultured bronchial epithelial
cells, proinflammatory cytokines induced an increase in
the protein expression of both PlGF and VEGF. Continuous
concomitant treatment with PlGF, TNF-a and IL-8
stimulation reduced VEGF expression and induced cell
death. This phenomenon was suppressed by VEGF
receptor inhibitor (CBO-P11).
Conclusions: The serum and BAL fluid levels of PlGF are
increased in patients with COPD and are inversely
correlated with FEV1. Concomitant treatment with PlGF,
TNF-a and IL-8 causes detrimental effects on airway
epithelial cells. These data suggest that bronchial
epithelial cells can express PlGF, which may contribute to
the pathogenesis of COPD.
The pathogenesis of chronic obstructive pulmon-
ary disease (COPD) is hypothesised to result from
an imbalance of proteases and antiproteases in the
lung.
1 The theory proposes that increased numbers
of neutrophils and macrophages, activated by
cigarette smoke, produce proteases and oxidants
that are responsible for the destruction of pulmon-
ary tissues.
2 However, in 1959, based on histologi-
cal examinations of lung tissues from patients with
pulmonary emphysema, Liebow noticed that the
alveolar septa in centrilobular emphysema appear
to be remarkably thin and almost avascular.
3 He
suggested that a reduction in the blood supply of
the small precapillary blood vessels might induce
the disappearance of alveolar septa. This ‘‘vascular
hypothesis’’ of COPD has been supported by the
results of a recent study in which the expression of
both vascular endothelial growth factor (VEGF)
and its receptor were shown to be decreased in
lung tissue from patients with COPD.
4 Besides,
cigarette smoke disrupts components of VEGF165
and its receptor VEGFR2 with decreased expression
of VEGF and its receptors in the lungs of rats and
humans.
5 The pathogenesis of COPD may there-
fore be more complex and multifactorial, resulting
from an interaction between genetic, environmen-
tal, cigarette smoke and angiogenesis factors.
Little is known about another angiogenic growth
factor called placenta growth factor (PlGF). PlGF is a
50 kDa glycosylated dimeric protein which shares
significant sequence homology at the amino acid
level with VEGF.
6 Like VEGF, PlGF exhibits mito-
genic activity on cultured endothelial cells and
induces angiogenesis in vivo, and its effects on
endothelial cells are similar to those of the potent
classical angiogenic factors such as VEGF and
fibroblast growth factor.
7 Receptors for VEGF, the
fms-like tyrosine kinase receptor (flt-1, VEGFR1) and
the kinase insert domain-containing receptor (KDR,
VEGFR2) are homodimeric, receptor tyrosine kinase.
While VEGF binds with high affinity to both flt-1
and KDR, PlGF exhibits high affinity binding only to
flt-1.
8 Normally, PlGF mRNA is present most
abundantly in the placenta, thyroid and lungs,
9 but
the biological function of PlGF in these tissues
remains unclear. A previous study has shown
significantly enlarged air spaces and enhanced
pulmonary compliance—a situation mimicking
human pulmonary emphysema—in PlGF transgenic
mice.
10It was the first study to suggest an association
between PlGF and pulmonary emphysema in mice,
but whetherit can be shown inhumans is unknown.
A study was undertaken to elucidate the role of
VEGF and PlGF in patients with COPD. We first
measured the levels of VEGF and PlGF in serum and
bronchoalveolar lavage (BAL) fluid from patients
with COPD. We then studied the regulation of PlGF
and VEGF in cultured bronchial epithelial cells after
exposure to various pro-inflammatory cytokines, as
well as the effects of 14 days exposure to heightened




Study population 1 consisted of 184 patients (152
men and 32 women) with smoking-related COPD.
Chronic obstructive pulmonary disease
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findings, physical examination and spirometric data, according
to the American Thoracic Society guidelines.
11 Inclusion criteria
for COPD included: chronic airway symptoms and signs such as
coughing, breathlessness, wheezing and chronic airway obstruc-
tion, which was defined as (1) ratio of forced expiratory volume
in 1 s to forced vital capacity (FEV1/FVC) ,70%; (2) FEV1
,80% of the predicted value via spirometric data; and (3) FEV1
reversibility after inhalation of 200 mg salbutamol of ,12% of
prebronchodilator FEV1. Subjects were excluded if they had a
history of asthma (reversibility of airflow obstruction) or
malignant lung disease.
The control group included 212 asymptomatic smokers or ex-
smokers (182 men and 30 women) with a smoking history of at
least 10 pack-years without clinical or laboratory evidence of
COPD and 159 never smokers (129 men and 30 women). All
were subjects who visited the hospital for a health examination.
All control subjects had normal pulmonary function (FEV1/FVC
.70% and FEV1 .80% of the predicted value) and no other co-
morbidities.
Peripheral blood was collected from patients with COPD and
controls in heparinised syringes and centrifuged within 15 min
of collection. The plasma was kept at 270uC until analysis by a
technician who was blinded to the condition of the patients.
Study population 2
Analysis of VEGF and PlGF levels in BAL fluid was also
performed in 20 patients with COPD and 18 controls (study
population 2). Haemoptysis was the indication for broncho-
scopy in most patients and controls, and BAL was performed if
there was no evidence of bleeding or bronchial lesions. Patients
with asthma, malignant lung disease or infectious processes in
the airway were excluded.
Bronchoalveolar lavage
Bronchoscopy was performed according to the standard proto-
col. After topical anaesthesia with 2% xylocaine, BAL was
performed with four 50 ml aliquots of phosphate buffered saline
instilled into the right middle lobe. The investigator made sure
that no blood component was found after normal saline
instillation and suction. The BAL fluid was aspirated into a
siliconised glass bottle and stored on ice until processing. The
chilled BAL fluid was strained through a single layer of coarse
gauze to remove clumps of mucus and then spun at 400g for
5 min to recover cells. If red blood cells were found the samples
were discarded. BAL fluid supernatant was collected and stored
at 280uC until analysis.
Measurement of VEGF, PlGF and cytokines in serum and BAL
fluid
Serum and BAL fluid levels of VEGF and PlGF were assayed by a
standardised sandwich enzyme-linked immunosorbent assay
(ELISA) method (R&D Systems, Minneapolis, MN, USA) in
duplicate according to the manufacturer’s protocol.
We calculated the concentrations of VEGF, PlGF and
proinflammatory cytokines (interleukin-1b (IL-1b), tumour
necrosis factor (TNF)-a, transforming growth factor (TGF)-b,
epidermal growth factor (EGF) and IL-8) divided by the albumin
concentration (pg/ml) in BAL fluid. The concentration of
albumin in the BAL fluid was assayed by the bromocresol green
method (Seiken, Tokyo, Japan). The amounts of VEGF, PlGF
and the cytokines in the BAL fluid were measured using an
ELISA assay (R&D Systems).
Bronchial epithelial cell line
S-cell (ATCC number CRL-9609) human bronchial epithelial
cells were grown in F12 nutrient mixture (GIBCO, Invitrogen
Corporation) with 0.5 ng/ml recombinant epidermal growth
factor, 500 ng/ml hydrocortisone, 0.005 mg/ml insulin,
0.035 mg/ml bovine pituitary extract, 500 nM ethanolamine,
500 nM phosphoethanolamine, 0.01 mg/ml transferrin, 6.5 ng/
ml 3,39,5-triiodothyronine, 500 ng/ml epinephrine and 0.1 ng/
ml retinoic acid. Cells were grown to confluence in medium
supplemented with 10% fetal calf serum which was then
replaced with serum-free medium for experiments.
Cell culture experiments
The effects of IL-1b, TNF-a, TGF-b, EGF and IL-8 (all purchased
from R&D Systems) on the expression of VEGF and PlGF in
lung epithelial cells were tested. These cytokines were selected
because they are proinflammatory cytokines and play impor-
tant roles in the pathogenesis of COPD.
12 Final concentrations
were 10 ng/ml for each cytokine.
The effect of PlGF on VEGF in lung epithelial cells was
investigated by daily treatment with various agents including
PlGF (50 pg/ml), TNF-a (200 pg/ml) and IL-8 (200 pg/ml),
individually or concomitantly. The concentrations of cytokines
were chosen because they were the mean levels of each cytokine
in BAL fluid samples from patients with COPD.
The cells were treated for 14 days and VEGF expression in the
conditioned media was evaluated. The conditioned media were
subjected to the ELISA assay according to the manufacturer’s
guidelines. Proteins (75 mg) extracted from treated cells were
subject to electrophoresis on 10% gradient Bio-Tris gels (Novex,
San Diego, California, USA) and transferred to PolyScreen





Age (years) 71.9 (8.0){ 69.2 (8.0) 74.7 (3.7)
Sex (M/F) 152/32 182/30 129/30
Smoking (pack-years) 36.6 (11.5){ 33.2 (12.8) 0
FEV1 (% pred) 47.2 (16.3)1 103.2 (13.7) 96.6 (15.4)
FEV1/FVC 45.8 (8.6)" 79.2 (5.9) 77.5 (7.2)
Serum VEGF (pg/ml) 282.7 (13.3)** 318.4 (19.6) 296.8 (26.1)
Serum PlGF (pg/ml) 27.1 (7.4)* 12.3 (5.1) 10.8 (6.3)
All values are shown as mean (SE).
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; VEGF, vascular
endothelial growth factor; PlGF, placenta growth factor.
*p=0.005; {p=0.33; {p=0.12; 1p,0.001; "p ,0.001; **p=0.35 (F test between the three groups).
Chronic obstructive pulmonary disease
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Bedford, Massachusetts, USA). The primary antibodies (1:1000
dilution) were anti-human VEGF165 and anti-human actin
(R&D Systems). The secondary antibody was anti-goat horse-
radish peroxidase-conjugated antibody (BioSource
International, Camarillo, California, USA). VEGF165 was
selected as being a pivotal form of the VEGF family and
essential to VEGF function.
The percentage of dead cells was determined by trypan blue
exclusion. Spontaneous uptake of trypan blue as a vital dye by
cells was then assessed by light microscopy. Apoptosis analysis
for S-cells was performed using the HTS caspase-3 assay
(Oncogene Research Products, San Diego, California, USA)
according to the manufacturer’s protocol at different time
points.
In a set of cells treated concomitantly with PlGF, TNF-a and
IL-8, a VEGF receptor inhibitor, CBO-P11 (Calbiochem, San
Diego, California, USA), was added in a concentration of 1 mM
at which the binding of VEGF165 to VEGFR1 (IC50=700 nM)
was blocked but the binding to VEGFR2 (IC50=1.3 mM) was
preserved.
13 The influence of CBO-P11 on VEGF expression and
S-cell apoptosis was examined. The dose-response of CBO-P11
was also tested with concentrations from 10 nM to 1 mMo n
day 14 of concomitant treatment with PlGF and cytokines to
determine the EC50 for CBO-P11 in preventing VEGF suppres-
sion and apoptosis.
Data analysis
All the data are expressed as mean (SE) for normally distributed
data. Statistical analysis was performed using SPSS 9.0 for
Windows (SPSS Inc, Chicago, Illinois, USA) and analysed using
post hoc testing (Scheffe test) for multiple comparisons and
linear regression. A p value of ,0.05 was considered statistically
significant.
RESULTS
Age, sex, smoking history and pulmonary function data of
patientswithCOPD and control subjects(studypopulation 1)are
summarisedintable1.Therewerenosignificantdifferencesinage
or smoking history between patients with COPD and controls.
There was no significant difference in the mean (SE) serum
levels of VEGF between patients with COPD and controls
(COPD: 282.7 (13.3) pg/ml; smokers: 318.4 (19.6) pg/ml;
Figure 1 Correlation between the serum concentration of placenta
growth factor (PlGF) and forced expiratory volume in 1 s (FEV1)
percentage predicted in patients with COPD (r=20.59, p=0.002). The
serum levels of PlGF were inversely correlated with FEV1.
Figure 2 (A) Concentrations of vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) in bronchoalveolar lavage (BAL) fluid in
patients with chronic obstructive pulmonary disease (COPD) and controls (*p=0.005, **p=0.002). Error bars are presented as standard errors. (B)
Concentrations of cytokines in BAL fluid in patients with COPD and controls. IL-1b, interleukin-1b; TNF-a, tumour necrosis factor-a; TGF-b,
transforming growth factor-b; EGF, epidermal growth factor; IL-8, interleukin-8. (*p=0.003; **p=0.001; {p=0.005; {p=0.003; ***p=0.001).
Error bars are presented as standard errors. The coefficients of variation within and between batches were 0.17 and 0.24, respectively. (C) Relationship
between PlGF levels in BAL fluid and forced expiratory volume in 1 s (FEV1) percentage predicted in patients with COPD (r=20.51, p=0.001). Higher
PlGF levels in BAL fluid correlated with worse lung function.
Table 2 Age, sex, smoking and pulmonary function data in patients




Age (years) 51.4 (12.8){ 45.6 (9.5)
Sex (M/F) 18/2 8/10
Smoking (pack-years) 18.3 (11.9){ 15.6 (10.2)
FEV1 (% pred) 73.4 (7.8)1 94.8 (10.1)
FEV1/FVC 63.1 (6.4)" 83.5 (4.6)
Albumin in BAL fluid (mg/ml) 0.13 (0.03)** 0.11 (0.06)
Serum VEGF (pg/ml) 298.7 (37.6){{ 321.9 (30.3)
Serum PlGF (pg/ml) 22.4 (9.7)* 13.2 (7.8)
All values are shown as mean (SE).
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; BAL, bronchoalveolar
lavage; VEGF, vascular endothelial growth factor; PlGF, placenta growth factor.
*p,0.05; {p=0.41; {p=0.38; 1p=0.007; "p= 0.006; **p=0.57; {{p=0.47.
Chronic obstructive pulmonary disease
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between the three samples). However, the serum levels of PlGF
weresignificantlyhigherinpatientswithCOPD(27.1 (7.4) pg/ml
than in the controls (smokers: 12.3 (5.1) pg/ml; non-smoker
controls: 10.8 (6.3) pg/ml, p=0.005). Moreover, the serum levels
of PlGF correlated inversely with the value of FEV1 in patients
with COPD (r=20.59, p=0.002; fig 1). Patients with higher
PlGF levels tended to have lower FEV1 values.
The characteristics of the 38 subjects (study population 2)
receiving bronchoscopic examination and BAL are presented in
table 2. The serum levels of PlGF were still significantly higher
in patients with COPD (22.4 (9.7) pg/ml than in controls (13.2
(7.8) pg/ml, p,0.05), but the serum concentrations of VEGF
were similar in the two groups. The concentrations of VEGF
and PlGF in the BAL fluid of patients with COPD and controls
are shown in fig 2A. The levels of VEGF were significantly lower
Figure 3 (A) Effect of persistent stimulation with exogenous PlGF, TNF-a or IL-8 on VEGF expression in S-cells. There was no significant difference in
VEGF levels in individual exposures from day 1 to day 14 ({p=0.24, {p=0.31, 1p=0.16 from day 1 to day 14 individually. Error bars are presented
as standard deviations. (B) Effect of persistent stimulation with a combination of TNF-a and IL-8 on VEGF expression in S-cells. Western blotting and
ELISA analysis show VEGF expression from day 1 to day 14. There was no statistical difference during this period ({p=0.43); C, control at day 14.
Error bars are presented as standard deviations. (C) Effect of persistent stimulation with a combination of PlGF, TNF-a and IL-8 on VEGF suppression in
S-cells. Western blotting and ELISA analysis show VEGF expression from day 1 to day 14. There was a statistically significant difference from day 7 to
day 14 with gradual downregulation of VEGF expression (*p,0.05); C, control at day 14. Error bars are presented as standard deviations. (D)
Percentage S-cell viability following stimulation with a combination of PlGF, TNF-a and IL-8 measured by trypan blue exclusion. The percentage of cell
deaths was significantly increased after 14 days of cytokine exposure (**p,0.05 vs day 7). Error bars are presented as standard deviations. (E)
Caspase-3 activity assay in S-cells after stimulation with a combination of PlGF, TNF-a and IL-8. The signal was analysed after subtracting the
appropriate number of cells/buffer controls. Caspase-3 activity gradually increased after 14 days of exposure (**p,0.01 vs day 7). Error bars are
presented as standard deviations. VEGF, vascular endothelial growth factor; PlGF, placenta growth factor; TNF-a, tumour necrosis factor-a; IL-8,
interleukin-8; RFU, relative signal.
Chronic obstructive pulmonary disease
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(30.1) pg/ml vs controls 237.8 (36.1) pg/ml, p=0.002).
However, the concentrations of PlGF in patients with COPD
were higher than those of controls (COPD 45.7 (12.3) pg/ml vs
controls 23.9 (7.6) pg/ml, p=0.005; table 2). The levels of
proinflammatory cytokines in BAL fluid from patients with
COPD (IL-1b: 143.4 (37.9), TNF-a: 205.7 (46.1), TGF-b: 89.5
(35.1), EGF:104.3 (40.7) and IL-8: 216.8 (38.9) pg/ml) were also
significantly higher than those from controls (IL-1b: 29.8 (13.6),
TNF-a: 30.5 (17.2), TGF-b: 17.4 (8.5), EGF: 21.3 (11.6) and IL-8:
40.2 (18.3) pg/ml; fig 2B). Moreover, higher BAL fluid levels of
PlGF were significantly correlated with worse lung function
represented by FEV1 (r=20.51, p=0.001; fig 2C). The levels of
VEGF in BAL fluid did not correlate with FEV1 (r=0.12,
p=0.51).
Effect of cytokines on PlGF and VEGF expression
After exposure to proinflammatory cytokines (IL-1b, TNF-a,
TGF-b and EGF), the expression of PlGF by S-cells increased
with time. PlGF protein levels were increased 2–3-fold at 6 h
and by 4–5-fold at 18 h. The levels of VEGF were also
significantly increased after stimulation with the same cyto-
kines. VEGF expression increased continuously from 6 to 18 h
of culture with IL-1b, TNF-a and IL-8. However, VEGF levels
cultured with TGF-b and EGF fell at 18 h.
Effect of persistent stimulation with PlGF, TNF-a and IL-8 on
VEGF expression
The expression of VEGF after 14 days of treatment with PlGF,
TNF-a or IL-8 using concentrations close to those in the BAL
fluid of patients with COPD (PlGF 50 pg/ml, TNF-a 200 pg/ml
and IL-8 200 pg/ml) is shown in fig 3A. With TNF-a or IL-8
stimulation alone, the expression of VEGF gradually increased
during the initial 7 days and then decreased after 10–14 days of
treatment. The same finding was noted after concomitant
treatment with TNF-a (200 pg/ml) and IL-8 (200 pg/ml) for
10 days (fig 3B). After 10 days exposure to 50 pg/ml PlGF alone
the level of VEGF decreased (fig 3A), but the expression of VEGF
was significantly reduced after 10 days of concomitant treat-
ment with PlGF (50 pg/ml), TNF-a (200 pg/ml) and IL-8
(200 pg/ml) (fig 3C). A cell viability test showed a significant
increase in the percentage of dead cells after cytokine exposure
for 14 days (fig 3D). Apoptosis analysis with the caspase-3
activity assay showed a considerable increase in apoptotic cells
during the 14 days of stimulation (fig 3E). The addition of
VEGFR inhibitor (CBO-P11) in a concentration that mainly
blocked VEGFR1 binding throughout the 14-day experimental
period to the mixture of TNF-a, IL-8 and PlGF avoided the
suppression of VEGF expression (fig 4A), maintained S-cell
viability (fig 4B) and prevented apoptosis (fig 4C). CBO-P11
prevented the suppression of VEGF expression in a dose-
dependent manner (fig 5A) with an EC50 of 415 nM (fig 5B).
The caspase-3 activity was also ameliorated with increasing
doses of CBO-P11 (fig 5C).
DISCUSSION
In this study we have demonstrated the potential mechanism of
PlGF in the pathogenesis of COPD. The expression of PlGF
increases as a response of airway epithelial cells to proinflam-
matory cytokines. The sustained stimuli of cytokines and PlGF
subsequently reduces VEGF expression and promotes the
apoptosis of airway epithelial cells through VEGFR. The
apoptosis of epithelial cells is considered essential for the
pathogenesis of pulmonary emphysema.
This study has several limitations. First, the numbers of men
and women were not balanced and a relatively small population
was recruited, especially in study population 2 in which there
were few patients with severe COPD. In Taiwan about 90% of
patients with COPD and chronic smokers are men.
Furthermore, it is difficult to perform bronchoscopy in patients
with severe obstructive lung function because of the invasive
nature of the procedure and poor baseline status. Second, BAL
Figure 4 (A) Effect of persistent stimulation with a combination of PlGF,
TNF-a,I L - 8a n dC B O - P 1 11mM/l on VEGF expression in S-cells. Western
blotting and ELISA analysis show VEGF expression from day 1 to 14. There
was no statistically significant difference during this period (*p=0.52); C,
control at day 14. Error bars are presented as standard deviations. (B)
Percentage S-cell viability followingstimulation witha combination of PlGF,
TNF-a,I L - 8a n dC B O - P 1 1m e a s u r e db yt r y p a nb l u ee x c l u s i o n .T h e
percentage of cell deaths was not significantly increased after 14 days of
exposure ({p=0.61 vs day 7). Error bars are presented as standard
deviations. (C) Caspase-3 activity assay for S-cells after stimulation with a
combination of PlGF, TNF-a, IL-8 and CBO-P11. The signal was analysed
after subtracting the appropriate number of cells/buffer controls. Caspase-3
activity did not increase after 14 days of exposure ({p=0.37 vs day 7).
Error bars are presented as standard deviations. VEGF, vascular endothelial
growthfactor;PlGF,placentagrowthfactor;TNF-a, tumour necrosis factor-
a; IL-8, interleukin-8; RFU, relative signal.
Chronic obstructive pulmonary disease
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blood clot and the samples were discarded if they were
obviously haemorrhagic. However, we still could not be sure
that there were no microscopic red blood cells which would
affect the measurement of PlGF expression. Third, the S-cell line
comprised transformed cells from primary airway epithelial
cells; it is unknown whether the expression of VEGF and PlGF
in S-cells could represent primary cells.
Previous studies have focused on the downregulation of VEGF
and VEGFR2 in emphysematous lung tissue.
4 In this study we
have confirmed the reduced expression of VEGF in patients with
COPD by measuring the levels of VEGF in BAL fluid. On the
other hand, the serum and BAL fluid levels of PlGF (a VEGF
homologue) increased in patients with COPD compared with
smokers with normal lung function.
PlGF expression increases significantly in early gestation,
peaks at around 26–30 weeks and decreases as term
approaches.
14 The biological function of PlGF after gestation
and in adulthood remains unclear. The cell origins of PlGF are
also unknown. Although there is evidence that synergism
between VEGF and PlGF contributes to angiogenesis and plasma
extravasation in pathological conditions such as in ischaemia or
inflammation,
15 we have shown that bronchial epithelial cells
can express PlGF and the levels of PlGF are increased in patients
with COPD.
We found that the serum concentrations of PlGF in patients
with COPD were inversely correlated with FEV1, and higher
BAL fluid levels of PlGF were seen in patients with worse
airflow limitation. The increased levels of PlGF in patients with
COPD may result from the stimulation of proinflammatory
mediators, as we found an increase in proinflammatory
cytokines in BAL fluid of patients with COPD and a bronchial
epithelial cell line (S-cells) was shown to express PlGF after
exposure to a variety of proinflammatory cytokines. The
relationship between serum or BAL fluid levels of PlGF and
lung function, even if statistically significant, does not
necessarily imply a cause and effect association.
Tsao et al
10 have previously shown that PlGF transgenic mice
develop pathology similar to human pulmonary emphysema.
Our study is the first to investigate the potential role of PlGF in
the pathogenesis of COPD in humans. Based on the findings of
our work, we propose the following hypothesis to explain the
possible role of increased levels of PlGF in the pathogenesis of
COPD. The expression of PlGF is increased secondary to the
stimuli of various inflammatory mediators participating in the
pathogenesis of COPD, and the increase in PlGF—acting in
combination with the inflammatory mediators—leads to the
death of airway epithelial and endothelial cells. Tsao et al
showed that PlGF inhibits the proliferation of MLE-15 cells (a
mouse pulmonary type II epithelial cell line) in a dose-
dependent manner and significantly promotes the death of
these cells.
10 In our study, persistent treatment of PlGF,
combined with TNF-a and IL-8, induced downregulation of
VEGF in the human bronchial epithelial cells most likely
through reducing the number of viable cells and increasing cell
apoptosis. Since the concentrations of PlGF, TNF-a and IL-8
used in cell cultures were close to those measured in BAL fluid in
patients with COPD, our finding could be pathologically
relevant. We have shown in vitro that the chronic stimulation
of epithelial cells with PlGF and other cytokines induces cell
death and apoptosis, which is similar to the exposure to chronic
irritants associated with lung parenchymal damage in vivo. We
have also shown that this phenomenon can be abolished by a
VEGFR inhibitor in a concentration mainly blocking VEGFR1.
Since VEGFR1 is the receptor of PlGF, the latter is then
considered to play an important role in the pathogenesis of
COPD. Based on the available evidence, increased PlGF levels
can be acknowledged as one factor—acting in combination with
multiple cytokines—in the multifactorial pathogenesis of
COPD.
We are aware that only 10–15% of smokers develop COPD. In
our study, smokers with normal lung function had serum PlGF
levels close to those in non-smokers despite consuming an equal
amount of cigarettes to smokers with COPD. The non-COPD
smokers also had fewer proinflammatory cytokines in the BAL
fluid than smokers with COPD. Host factors such as genetic
polymorphisms of susceptible genes may play an important role
in the development of COPD. Subjects carrying genetic variants
of increased function of detoxifying enzymes or a reduced
response of inflammatory cytokines may generate a lower
inflammatory response to cigarette smoke
16 17 so, based on our
hypothesis, they have lower PlGF expression and less smoking-
related damage to the lung parenchyma. It is also possible that
each individual may have different capabilities for expressing
PlGF under inflammatory stress, but further investigations are
needed to confirm this notion.
VEGF expression in the serum did not change, unlike the
expression of VEGF in the BAL fluid. Since the serum levels of
Figure 5 (A) S-cells were cultured with fixed concentrations of PlGF, TNF-a, IL-8 and the indicated concentrations of CBO-P11 for 14 days. The
expression of VEGF in conditioned medium was measured. Error bars are presented as standard deviations of triplicate. (B) Dose-response curve of
CBO-P11 showing an EC50 of 415 nM/l. (C) Caspase-3 activity assay of S-cells cultured with fixed concentrations of PlGF, TNF-a, IL-8 and the indicated
concentrations of CBO-P11 for 14 days. Error bars are presented as standard deviations. VEGF, vascular endothelial growth factor; PlGF, placenta
growth factor; TNF-a, tumour necrosis factor-a; IL-8, interleukin-8; RFU, relative signal.
Chronic obstructive pulmonary disease
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such as tissue hypoxaemia or inflammation, the expression of
both factors in BAL fluid should represent more accurately the
changes in lung parenchyma and reflect the real pathological
mechanisms of lung diseases.
COPD is traditionally classified into chronic bronchitis and
emphysema. The pathogenesis and clinical manifestations of
these two subtypes may be somehow different. However, few
biological markers can clearly differentiate one from the other.
Previous investigators have reported increased levels of VEGF in
induced sputum from patients with chronic bronchitis and
decreased amounts in patients with emphysema.
18 As far as we
know, cigarette smoke reduces VEGF and VEGF receptor
expression and signalling, resulting in pulmonary endothelial
cell death followed by progressive disappearance of the alveolar
septum.
19 Whether downregulation of VEGF resulting from
overexpression of PlGF contributes to the pathogenesis of
pulmonary emphysema or whether overexpression of VEGF
leading to airway and vessel remodelling contributes to chronic
bronchitis still needs to be elucidated. Previous investigators
have reported contradictory findings regarding VEGF expression
in COPD. Kranenberg et al
20 demonstrated enhanced bronchial
expression of VEGF and its receptors in patients with COPD.
However, Kanazawa and Yoshikawa
21 showed that sputum
levels of VEGF decreased with the severity of COPD, a finding
similar to ours. These authors later reported an increase in
sputum VEGF levels in patients with ‘‘bronchitis-type’’ COPD.
22
The above findings reflect the nature of COPD as a disease
spectrum with variable phenotypes—emphysema, chronic
bronchitis, or mostly mixed; the role of angiogenesis should be
different in each phenotype. Further investigations are required
to recruit more patients with COPD in order to focus on specific
pathological changes or phenotypes to clarify the role of these
two angiogenic growth factors in COPD.
In summary, our results suggest that the levels of PlGF are
increased in patients with COPD, which might contribute to
the pathogenesis of COPD. Subjects with higher PlGF levels in
serum and BAL fluid had worse lung function. This study also
shows that human bronchial epithelial cells can express PlGF,
and continuous stimulation of PlGF and proinflammatory
cytokines can suppress VEGF. Persistent PlGF expression might
have adverse effects on lung parenchyma by downregulating
angiogenesis. The mechanisms behind the observed detrimental
effects of PlGF remain to be clarified.
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